Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
Long-term HIV-1 infection induces an antiviral state in primary macrophages.
Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1.
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents.
The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.
Cyclin D3-dependent control of the dNTP pool and HIV-1 replication in human macrophages.
SAMHD1 specifically affects the antiviral potency of thymidine analog HIV reverse transcriptase inhibitors.
Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile α motif and HD domain-containing protein-1 (SAMHD1) activity.
Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1.
Increased expression of SAMHD1 in a subset of HIV-1 elite controllers.